Skip to content

Osimernib

Generic Name
Osimertinib Mesylate
Therapeutic Area
Oncology
Therapeutic Class
Antineoplastic – EGFR Tyrosine Kinase Inhibitor
Dosage Form
Tablets
Strength
80 mg
Pack Size
30’s
Registration Number
130719

Overview

Osimertinib is a third-generation, oral EGFR tyrosine kinase inhibitor designed to target specific EGFR mutations, particularly exon 19 deletions and exon 21 L858R mutations. It plays an important role in the targeted management of eligible patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Indication

Treatment of specific types of non-small cell lung cancer (NSCLC) that have certain epidermal growth factor receptor (EGFR) gene mutations.